Skip to main content
Premium Trial:

Request an Annual Quote

NIGMS Sets Aside $10M for Systems Bio Research; RFA Applications Due Nov. 1

NEW YORK (GenomeWeb News) - The National Institute of General Medical Sciences has set aside approximately $10 million dollars in fiscal year 2007 under a request for applications to fund three new and/or competing continuation grants in the field of systems biology.
Specifically, the NIGMS said it will fund studies that "promote institutional development of pioneering research, training, and outreach programs focused on systems level analysis of biological phenomena of biomedical importance within the NIGMS mission."
The NIH agency will support "fundamental inquiries focused on molecular and cell biology, biophysics, genetics and developmental biology, pharmacology, anesthesiology, and human physiology in the areas of trauma, burn, inflammation, and multi-organ failure," the RFA said.
The RFA, which is a 2004 reissue, covers:
  • "Signaling networks and the regulatory dynamics of cellular processes such as cell cycle control, transient complex formation, organelle biogenesis, and intercellular communications;
  • "Supramolecular machines, such as the replisome, spliceosome, and molecular motor assemblies in cell division and motility;
  • "Pattern formation and developmental processes in model systems (e.g., Drosophila, C. elegans, etc.);
  • "Metabolic networks and the control of the flux of substrates, intermediates, and products in cell physiology;
  • "Organ system networks involved in multi-organ failure in shock, trauma, and burn injury; and
  • "Architecture of biological complexity related to inherited variation and its environmental context."
Applicants may request a project period of up to five years and a budget for direct costs up to $2 million per year,. NIGMS said. They may ask for more than this amount to pay for "initial large equipment" purchases, with certain restrictions.
Letters of intent should be received by Oct. 23 and applications should be received by Nov. 1, according to the NIGMS. Earliest anticipated start date is July 1, 2007.
Additional information can be found here.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.